General Myelodysplastic Syndrome


Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes (August 31, 2016)

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but... Continue Reading

About PCROWD, Dana-Farber’s tissue-banking study for patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes (June 27, 2016)

PCROWD (“Precursor CROWDsourcing”) – a tissue banking and clinical information study and repository – is an indispensable component of the blood cancer research pipeline. The main objective... Continue Reading

Prospective Study Shows Age Doesn’t Affect Survival Outcomes in Patients with Myelodysplastic Syndrome (MDS) Who Receive a Hematopoietic Cell Transplant (HCT) (December 14, 2015)

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (August 8, 2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s... Continue Reading

Regular Use of Acetaminophen May Increase Risk of Blood Cancers (May 13, 2011)

Long-term, regular use of acetaminophen (Tylenol®) may increase the risk of leukemia and lymphoma. These results were published in the Journal of Clinical Oncology. Some studies have suggested that use... Continue Reading

Fewer Lung Cancer Deaths Among Women (April 11, 2011)

The lung cancer death rate among women appears to be declining for the first time in 40 years, according to an annual report published by multiple institutions. Findings from the report were recently released... Continue Reading

Cancer Care Costs Expected to Rise by at Least 27% Over Next Decade (January 18, 2011)

As a result of the growth and aging of the US population, cancer care costs are expected to rise by 27% by the year 2020. This estimate does not include increases in the cost of cancer treatment itself,... Continue Reading

Vidaza® Improves Survival in Higher-risk Myelodysplastic Syndromes (March 6, 2009)

According to the results of a Phase III clinical trial, treatment with Vidaza® (azacitidine) results in better survival than conventional care among patients with higher-risk myelodysplastic syndromes... Continue Reading

The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies (January 30, 2009)

The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies The 2008 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois,... Continue Reading

New Risk Model for MDS Applies to All Stages of Disease (December 31, 2008)

New Risk Model for MDS Applies to All Stages of Disease A new risk model for myelodysplastic syndrome (MDS) provides survival projections for all stages of the disease and has proven superior to the International... Continue Reading

Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants (December 30, 2008)

Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants Age should not be a barrier for non-myeloablative allogeneic stem cell transplantation in patients with acute... Continue Reading

Vidaza® Approved for High-risk MDS (August 22, 2008)

Vidaza® Approved for High-risk MDS The US Food and Drug Administration (FDA) has approved Vidaza® (azacitadine) for the treatment of high-risk myelodysplastic syndromes. Vidaza is already approved for... Continue Reading

Updates in the Management of Myelodysplastic Syndromes (January 21, 2008)

Updates in the Management of Myelodysplastic Syndromes: A Report from the 2007 American Society of Hematology (ASH) Meeting IntroductionCytopenias – The Double-Edged SwordHypomethylating Agents – Living... Continue Reading

Supportive Care and Hematologic Malignancies (January 21, 2008)

Supportive Care and Hematologic Malignancies: A Report from the 2007 American Society of Hematology (ASH) Meeting Introduction At the 2007 meeting of the American Society of Hematology (ASH) the most interesting... Continue Reading

Vidaza Improves Survival in High-risk Myelodysplastic Syndrome (December 11, 2007)

Vidaza Improves Survival in High-risk Myelodysplastic Syndrome According to results recently presented at the 2007 annual meeting of the American Society of Hematology (ASH), the agent Vidaza® (azacitidine)... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS